Amanda Timek, Catherine Daniels-Brady, Stephen Ferrando
preprint
Abstract Background : Anorexia nervosa is a life-threatening psychiatric illness with a high mortality rate and limited treatment options. This illness is frequently comorbid with major depressive disorder, leading to additional obstaces in patient quality of life, and increasing the mortality rate further due to risk of suicide. Ketamine, an competitive N-methyl-D-aspartate receptor...
Research Square
Jack Swain, Davis Carter, Leonardo Vando et al.
preprint
Abstract Background Sleep disturbances are a significant public health burden affecting 50 to 70 million adults in the United States and contributing to impaired cognition, accelerated disease progression, and increased mortality risk. 1,2 Available pharmacological treatments carry notable safety and tolerability risks, while access to the leading evidence-based behavioral intervention,...
Research Square
Norihiro Okada, Kenshiro Oshima, Akiko Maruko et al.
preprint
Abstract In response to a state of stress, the body attempts to maintain protein homeostasis through intron retention (IR). In other words, by examining which genes undergo IR under stress (i.e., IR genes), it is possible to analyze what type of stress the body is experiencing (Okada et al. 2024 Front.Psychiatry). Using this principle, we re-analyzed the RNA-seq data of non-responders and...
Research Square (Research Square)
Adam Włodarczyk, Wiesław Jerzy Cubała, Maria Węgielnik-gałuszko et al.
preprint
Abstract Background and objectives: There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety and tolerability concerns arise regarding adverse drug reactions and specific subpopulations. The aim of this paper is to investigate the relationship between dissociative and psychometric measures in course of intravenous ketamine treatment in TRD inpatients with Major...
Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al.
4 citations
preprint
Treatment resistant depression (TRD) is a tremendous health problem that has encouraged novel treatment strategies involving sub-anesthetic ketamine infusions. While ketamine induces rapid and sustained clinical improvement, its cognitive effects are less well known. Here we tested if ketamine alters the negative expectancies about the future that are insensitive to disconfirming information,...
Adam Włodarczyk, Wiesław Jerzy Cubała, Maria Węgielnik-gałuszko et al.
1 citation
preprint
Abstract Background and objectives: There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions and specific subpopulations. The aim of this paper is to investigate the safety of intravenous ketamine treatment concerning dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and...
Research Square
Alice Le Berre
preprint
Abstract Background: Treatment-resistant depression (TRD) involves impaired hippocampal plasticity. Preclinical work showed synaptic potentiation and dendritic spine growth in the dentate gyrus (DG) after esketamine (ESK), but human evidence is lacking. We aimed to detect early DG changes after ESK using advanced diffusion MRI, and to test whether baseline MRI metrics predict clinical response....
Research Square
Taqwa B. Thanoon, Zeina A. Althanoon
preprint
Abstract Maternal depression during pregnancy adversely affects offspring neurodevelopment and behaviour. Typical antidepressants like selective serotonin reuptake inhibitors have limitations due to risks of crossing the placenta. Ketamine has emerged as a promising alternative treatment. This research examined ketamine's effects on offspring of maternally stressed mice. Dams were divided into...
SSRN Electronic Journal
Michael Alvear
preprint
Background: Oral and sublingual ketamine for depression is being prescribed to tens of thousands of patients through telehealth services with no FDA-approved dosing protocol, no clinical guideline covering this route of administration, and no publicly available synthesis of what clinical researchers have actually tested. A prior surveillance study of patient-reported experiences documented a...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...